Dupilumab, an interleukin (IL)-4 and IL-13 binding monoclonal antibody (Ab), and tralokinumab-ldrm, an IL-13 binding monoclonal Ab, are human monoclonal IgG4 biologics that have demonstrated efficacy in the treatment of moderate-to-severe atopic dermatitis [1]. Here, IL13 is linked to atopic eczema.